Seer, Inc. (NASDAQ:SEER) Sees Large Decrease in Short Interest

Seer, Inc. (NASDAQ:SEER) was the target of a significant drop in short interest in the month of April. As of April 15th, there was short interest totaling 432,590 shares, a drop of 40.9% from the March 31st total of 732,581 shares. Based on an average daily trading volume, of 506,721 shares, the short-interest ratio is currently 0.9 days. Approximately 0.9% of the shares of the company are short sold.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Occudo Quantitative Strategies LP acquired a new position in shares of Seer in the 2nd quarter worth approximately $25,000. Marshall Wace LLP acquired a new position in shares of Seer in the 4th quarter worth approximately $85,000. Quadrature Capital Ltd acquired a new position in shares of Seer in the 4th quarter worth approximately $101,000. Barclays PLC boosted its holdings in shares of Seer by 685.0% in the 4th quarter. Barclays PLC now owns 60,717 shares of the company’s stock worth $111,000 after acquiring an additional 52,982 shares in the last quarter. Finally, Corient Private Wealth LLC acquired a new position in shares of Seer in the 4th quarter worth approximately $116,000. Institutional investors own 75.20% of the company’s stock.

Seer Price Performance

NASDAQ:SEER opened at $1.97 on Monday. Seer has a 12-month low of $1.65 and a 12-month high of $2.41. The firm has a market capitalization of $111.15 million, a PE ratio of -1.54 and a beta of 1.59. The firm has a 50-day moving average price of $1.84 and a 200 day moving average price of $1.92.

Seer (NASDAQ:SEER) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.03. Seer had a negative net margin of 443.96% and a negative return on equity of 26.04%. The firm had revenue of $4.20 million during the quarter, compared to analyst estimates of $4.60 million.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on SEER shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Seer in a research note on Tuesday, April 21st. TD Cowen upgraded shares of Seer to a “strong-buy” rating in a research note on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Seer presently has an average rating of “Moderate Buy”.

Seer Company Profile

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.